

Special Issue

Vaccine Strategies to Prevent Community-Acquired Pneumonia

Message from the Guest Editors

Community-acquired respiratory infections are defined as respiratory infections that are acquired outside the hospital. Healthcare systems are currently facing several treatment challenges based on the increasing occurrence of antibiotic-resistant strains and the high rates of recurrent infections occurring. Influenza causes seasonal outbreaks globally, while pneumococcus is still the most frequent causative pneumonia pathogen. The use of currently widely available influenza and pneumococcal vaccines has remained suboptimal. Strategies to prevent community-acquired respiratory infections need further improvement. These include the development of new and improved vaccines, improved environmental control, the accurate and immediate diagnosis, timely and appropriate therapy, and new approaches such as hospital-based immunization. Targeted strategies should consider patient groups with risk factors like advanced age, chronic lung disease, cardiovascular disease, diabetes mellitus, malnutrition, immunocompromising conditions, smoking, and excessive alcohol consumption. We invite researchers working on this field to submit their work to this Special Issue by August 2024.

Guest Editors

Dr. Vissaria Sakka

3rd Department of Internal Medicine and Laboratory, School of Medicine, NKUA, Sotiria General Hospital, Athens, Greece

Dr. Garyphallia Poulakou

3rd Department of Internal Medicine and Laboratory, School of Medicine, NKUA, Sotiria General Hospital, Athens, Greece

Deadline for manuscript submissions

28 February 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/192461

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).